TG Therapeutics (NASDAQ: $TGTX), a commercial-stage biopharmaceutical company, released its Q4 fiscal 2024 results on Monday, March 3, 2025, before markets opened. Here is a deep dive into the company’s Q4 results.
TG Therapeutics Earnings Results
For the fourth quarter of fiscal year 2024, TG Therapeutics reported revenue of $108.19 million, compared to $43.97 million in Q4 of fiscal year 2023. Analysts had forecasted Q4 revenue of $98.5 million.
Net income came in at $23.33 million, for a diluted EPS of $0.15. That was a huge improvement from a net loss of $14.42 million or a diluted net loss of $0.10 per share.
For fiscal 2024, revenue came in at $329 million, and a net income of $23.38 million or $0.15 per share. This was a huge improvement from fiscal 2023, when it reported revenue of $233.66 million, and a net income of $12.67 million, or $0.09 per share.
The company ended fiscal 2024 with $311M in cash, and cash equivalents. Its total assets were valued at $577.69M, while its total equity was valued at $222.36 million.
Other Highlights
Most of TG Therapeutics’ revenue came from BRIUMVI, which generated $103.6 million in Q4 and $310 million in the fiscal year 2024. It announced the launch of BRIUMVI in Europe with its partner, Neuraxpharm.
The company also presented data from its Phase 3 trial for the use of BRIUMVI in the treatment of relapsing multiple sclerosis (RMS), which shows great promise. TG Therapeutics also announced the launch of several phase 1 trials.
Commenting on the results, CEO Michael S. Weiss stated, “These accomplishments provide a solid foundation as we look toward continued success in 2025.”
Fiscal 2025 Guidance
For full-year 2025, TG Therapeutics expects global revenue of around $540 million, including BRIUMVI US net product revenue of around $525 million. Additionally, it expects $300 million in operating expenses.
Market Performance
Following the revenue beat, TGTX shares soared 15.19% to $34.66 per share in early morning trading as of 9:53 AM EST. The stock is up 10.10% in the past month, 53.30% in the past six months, and 92.99% in the past 12 months.
Analysts give the stock a moderate buy rating, forecast an average price of $39.80, which is 13.55%. They give the stock a wide range of forecasts, with a high of $55, and a low of $10.
Should You Add TG Therapeutics To Your Portfolio in 2025?
TG Therapeutics had a great fourth quarter, and full year. Additionally, it has a great pipeline in the works, and it has expanded beyond the US into Europe. The company forecast growth in revenue in fiscal 2025 to over half a billion, which is an impressive accomplishment. Consequently, adding TGTX to your portfolio in 2025 could potentially lead to long-term gains.
Click Here For Updates on TGTX – It’s FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.
